Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 5/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | AR | P10275 | 3/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.60 |
| ▸ | PGR | P06401 | 2/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.60 |
| ▸ | SNCA | P37840 | 2/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.60 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21850133 | 1.00 | SHBG (0.79) | SHBGCYP3A4TSHRTHPOHIF1A | |
| SCHEMBL1682762 | 1.00 | SHBG (0.79) | SHBGCYP3A4TSHRTHPOHIF1A | |
| SCHEMBL22100655 | 1.00 | SHBG (0.79) | SHBGCYP3A4TSHRTHPOHIF1A | |
| SCHEMBL2733387 | 0.88 | SHBG (1.00) | SHBGCYP3A4TSHRTHPOHIF1A | |
| SCHEMBL9172697 | 0.88 | SHBG (1.00) | SHBGCYP3A4TSHRTHPOHIF1A | |
| SCHEMBL10274070 | 0.88 | SHBG (1.00) | SHBGCYP3A4TSHRTHPOHIF1A | |
| Clostebol SCHEMBL4437252 | 0.87 | SHBG (0.76) | SHBGCYP3A4TSHRTHPOHIF1A | |
| SCHEMBL10944734 | 0.87 | SHBG (0.76) | SHBGCYP3A4TSHRTHPOHIF1A | |
| Clostebol SCHEMBL146712 | 0.87 | SHBG (0.76) | SHBGCYP3A4TSHRTHPOHIF1A | |
| SCHEMBL28944454 | 0.87 | SHBG (0.76) | SHBGCYP3A4TSHRTHPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107206010-A | C-19 steroids to inhibit neovascularization | 库拉迪斯有限公司 | 2017-09-26 | — | — | CN | claimed |
| US-9610292-B2 | Uses for 4,17β-dihydroxyandrost-4-ene-3-one | MABEL GMBH (DE) | 2017-04-04 | — | — | US | claimed |
| EP-2060261-B1 | C-19 steroids for cosmetic uses | ATHENION AG (CH) | 2016-03-09 | — | — | EP | claimed |
| US-20160030448-A1 | Uses for 4, 17ß-dihydroxyandrost-4-ene-3-one | MABEL GMBH (DE) | 2016-02-04 | — | — | US | claimed |
| CN-101854979-B | The C-19 steroid of being used for the treatment of property application | PROCIMA GMBH (DE) | 2015-11-25 | — | — | CN | claimed |
| US-9138477-B2 | Uses for 4,17β-dihydroxyandrost-4-ene-3-one | MABEL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| US-9114163-B2 | Medication against breast cancer and related diseases | MABEL GMBH (DE) | 2015-08-25 | — | — | US | claimed |
| EP-2018170-B1 | Medication against breast cancer | MABEL GMBH (DE) | 2012-07-25 | — | — | EP | claimed |
| EP-2018169-B1 | USE OF 4,17 BETA-DIHYDROXYANDROST-4-ENE-3-ONE FOR TREATING CANCERS | MABEL GMBH (DE) | 2010-11-10 | — | — | EP | claimed |
| US-20100061975-A1 | Uses for 4,17B-dihydroxyandrost-4-ene-3-one | CURADIS GMBH (DE) | 2010-03-11 | — | — | US | claimed |
| US-20090111784-A1 | MEDICATION AGAINST BREAST CANCER AND RELATED DISEASES | CURADIS GMBH (DE) | 2009-04-30 | — | — | US | claimed |
| EP-2018169-A2 | USE OF 4,17 BETA-DIHYDROXYANDROST-4-ENE-3-ONE FOR TREATING CANCERS | Teichmann, Alexander Tobias (DE) | 2009-01-28 | — | — | EP | claimed |
| WO-2007131736-A2 | USE OF 4, 17 BETA-DIHYDROXYANDROST-4-ENE-3-ONE FOR TREATING CANCERS | TEICHMANN ALEXANDER TOBIAS (DE) | 2007-11-22 | — | — | WO | claimed |
| EP-1854465-A1 | Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers | Teichmann, Alexander Tobias (DE) | 2007-11-14 | — | — | EP | claimed |
| US-20030199487-A1 | Ester and ether derivatives of 4-hydroxytestosterone and a method for the regulation of athletic function in humans | Paternoster, Mr. Vince | 2003-10-23 | — | — | US | claimed |
| US-20210346385-A1 | TASTE-MASKED DOSAGE FORMS | DEEP OCEAN CAPITAL MANAGEMENT LP | 2021-11-11 | — | — | US | disclosed |
| EP-3172566-B1 | SAMPLE ANALYSING DEVICE | INTELLIGENT FINGERPRINTING LTD (GB) | 2019-10-16 | — | — | EP | disclosed |
| EP-1854465-A1 | Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers | Teichmann, Alexander Tobias (DE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20030199487-A1 | Ester and ether derivatives of 4-hydroxytestosterone and a method for the regulation of athletic function in humans | Paternoster, Mr. Vince | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111784-A1 | MEDICATION AGAINST BREAST CANCER AND RELATED DISEASES | CYP19A1, SHBG, ESRRB | SHBG 2/4885CYP3A4 277/4885TSHR 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.